Latest News

Servier to bag Shire's cancer business

Cancer cell and T cell, © fotolia.com/Science RF


by tg

French Servier boosts its cancer drug portfolio acquiring Shire plc’s oncology pipeline, which earned about US$260m last year, for US$2.4bn in cash. 

The deal includes the  acute lymphoblastic leukemia (ALL) drug pegaspargase (Oncaspar) and late stage ALL candidate drug calaspargase pegol plus the ex-US rights fort a nano-formulation of the chemotherapeutic irinotecan (Onivyde). Servier will also receive the rights on several licenced drug candidates including CAR-T cells developed by Precision Biosciences and checkpoint modulators co-developed with Symphogen vs several targets.

Shire’s divestment comes at a time where Japan’s oncology-focussed drugmaker considers to acquire the London-based  orphan drug and neurology specialist, who want to split both parts of the company. However, Deutsche Bank analysts said this was unlikely to be a deal breaker. A Takeda spokesman declined to comment. Under UK takeover regulations, Takeda has until April 25 to announce whether or not it will bid for Shire, which has a market value of about US$47bn.

EMA greenlights BioNtech's COVID-19 vaccine

It's the first time, that the European Medicines Agency (EMA) has recommended a mRNA vaccine. On Monday,  the drug agency cleared the way for...

EU approves second COVID-19 vaccine

The EU has secured a total of 160 million doses of mRNA-1273 from the US-American manufacturer Moderna, which has outsourced production sites on the...

Servier and MiNA Therapeutics sign €220m deal

Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

Galecto raise US$85m in Nasdaq IPO

The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m  Series D round, with a share price of...

Merry Christmas and a Happy New Year

Siemens launches COVID-19 antigen lateral flow test

As testing capacities for the SARS-CoV-2 gold standard RT-PCR are going to be exhausted upon the looming second wave of infections with the novel...

3P Bio to manufacture SpyBiotech vaccine

Under the agreement, Navarra-based CDMO 3P Biopharmaceuticals will produce cGMP lots for Phase I testing of SpyBiotech’s (Oxford) vaccine candidate...